IDEXX Laboratories, Inc.
IDXX
Rankning i aktier
#555
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing,... IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
Aktiekurs
$554.41
Marknadsvärde
$43.68B
Förändring (1 dag)
-0.63%
Förändring (1 år)
-12.98%
Land
US
Handel IDEXX Laboratories, Inc. (IDXX)
Kategori
Healthcare
P/E-tal för IDEXX Laboratories, Inc. (IDXX)
P/E-tal per October 2026 TTM: 37.15
Enligt IDEXX Laboratories, Inc. senaste finansiella rapporter och aktiekurs är det aktuella P/E-talet (TTM) 37.15. I slutet av 2024 hade företaget ett P/E-tal på 38.40.
Historik för P/E-tal för IDEXX Laboratories, Inc. från 2000 till 2026
P/E-tal vid slutet av varje år
| År | P/E-tal | Ändra |
|---|---|---|
| 2026 (TTM) | 37.15 | -27.37% |
| 2025 | 51.15 | 33.19% |
| 2024 | 38.40 | -29.62% |
| 2023 | 54.56 | 8.61% |
| 2022 | 50.24 | -33.30% |
| 2021 | 75.32 | 2.72% |
| 2020 | 73.33 | 39.47% |
| 2019 | 52.57 | 22.67% |
| 2018 | 42.86 | -17.83% |
| 2017 | 52.16 | 10.06% |
| 2016 | 47.39 | 34.81% |
| 2015 | 35.15 | -13.82% |
| 2014 | 40.79 | 35.48% |
| 2013 | 30.11 | 5.19% |
| 2012 | 28.62 | 5.96% |
| 2011 | 27.01 | -4.46% |
| 2010 | 28.28 | 9.95% |
| 2009 | 25.72 | 38.12% |
| 2008 | 18.62 | -51.50% |
| 2007 | 38.39 | 44.28% |
| 2006 | 26.61 | -11.05% |
| 2005 | 29.91 | 25.46% |
| 2004 | 23.84 | -14.17% |
| 2003 | 27.78 | 14.17% |
| 2002 | 24.33 | -3.56% |
| 2001 | 25.23 | 21.51% |
| 2000 | 20.76 | 0.00% |
P/E-tal för liknande företag eller konkurrenter
| Företag | P/E-tal | Skillnad i P/E-tal | Land |
|---|---|---|---|
| 36.15 | -2.68% |
US
|
|
| 39.77 | 7.06% |
US
|
|
| -290.26 | -881.32% |
US
|
|
| - | - |
CN
|
|
| 34.18 | -7.98% |
US
|
Hur man läser ett P/E-tal
P/E-talet (Price/Earnings) mäter förhållandet mellan ett företags aktiekurs och dess vinst per aktie.
Ett lågt men positivt P/E visar ett företag med hög vinst i förhållande till värderingen och kan vara undervärderat. Ett högt negativt (nära 0) P/E indikerar stora förluster.
Företag med P/E över 30 eller negativt ses ofta som "tillväxtaktier", vilket innebär att investerare förväntar sig tillväxt eller framtida lönsamhet.
Företag med positivt P/E under 10 ses som "värdeaktier" och är redan lönsamma men med begränsad tillväxtpotential.